Lupin Limited

LUPIN

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:15:59 2024-05-10 am EDT			5-day change	1st Jan Change
1,610 ^INR	+1.62%		-2.74%	+21.68%

May. 09	Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy	MT
May. 09	Lupin Limited Announces Board Appointments	CI

Lupin Limited Provides Earnings Guidance for the Second Half of 2021

August 11, 2021 at 09:30 am EDT

Lupin Limited provided earnings guidance for the second half of 2021. For the period, the company expects revenues to grow double digits, both in India and other parts, including America.

Latest news about Lupin Limited

Nomura Adjusts Lupin’s Price Target to INR1,952 From INR1,949, Keeps at Buy	May. 09	MT
Lupin Limited Announces Board Appointments	May. 09	CI
Jefferies Adjusts Lupin’s Price Target to INR1,535 From INR1,460 Keeps at Hold	May. 08	MT
Transcript : Lupin Limited, Q4 2024 Earnings Call, May 07, 2024	May. 07
Lupin's Consolidated Profit Climbs in Fiscal Q4; Shares Dip 4%	May. 07	MT
Indian drugmaker Lupin misses quarterly profit estimates as costs rise	May. 06	RE
Lupin Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 06	CI
Lupin Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 06	CI
Lupin Limited Receives an Order from Office of the State Tax Inspector, Jurisdiction: Ghatak 56: Range - 14: Division - 6: Gujarat	Apr. 30	CI
Lupin Receives US FDA Inspection Report for Aurangabad, India Manufacturing Facility	Apr. 23	MT
INDIA STOCKS-Indian shares rise tracking Asia rebound; drop in HDFC Bank caps gains	Apr. 22	RE
Lupin Launches Mirabegron Extended-Release Tablets in US	Apr. 21	MT
Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration	Apr. 20	CI
US FDA Clears Lupin's API Plant in Gujarat, India, Following GMP Inspection	Apr. 12	MT
Lupin Launches Generic Version of Oracea (Doxycycline Capsules) in US	Apr. 09	MT
Lupin Launches Generic Drug for Inflammatory Lesions of Rosacea in US	Apr. 09	MT
Lupin Limited Announces the Launch of First Generic Version of Oracea® (Doxycycline Capsules, 40 Mg), in the United States	Apr. 09	CI
Indian Equities Close with Marginal Loss on Wednesday as Traders Scale Down Hopes on US Rate Cuts	Apr. 03	MT
Lupin Names Chief Quality Officer	Apr. 03	MT
Lupin Limited Announces Change in Management	Apr. 03	CI
Lupin to Transfer Trade Generics Business to Subsidiary Lupin Life Sciences	Mar. 25	MT
Lupin Limited Receives an Order from the Additional Commissioner of State Tax, Central Division, Patna	Mar. 21	CI
Indian Equities Start Week in Black, Aided by Major Auto and Metal Firms	Mar. 18	MT
Lupin Names Chief Technical Operations Officer	Mar. 18	MT
Lupin Limited Appoints Christoph Funke as Chief Technical Operations Officer	Mar. 18	CI

Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lupin Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,610 INR

Average target price

1,547 INR

Spread / Average Target

-3.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LUPIN LIMITED	+21.68%	8.78B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

Lupin Limited

Equities

LUPIN

INE326A01037

Pharmaceuticals

Lupin Limited Provides Earnings Guidance for the Second Half of 2021

Latest news about Lupin Limited

Chart Lupin Limited

Company Profile

Income Statement Evolution

Ratings for Lupin Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals